Therefore, pharmacological interventions involving substances like metformin or SR-18292 have shown promise in inhibiting the effects associated with PGC1α upregulation, mitigating its impact on CCA progression and metastasis (105). The gene discussed is PPARGC1A; the disease is cholangiocarcinoma.